Treatment of Susac's syndrome

Current Treatment Options in Neurology

Volumn 10, Issue 1, 2008, Pages 67-74

  Rennebohm, Robert M ^a   Egan, Robert A ^a   Susac, John O ^a  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; ETANERCEPT; IMMUNOGLOBULIN; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; RITUXIMAB; TUMOR NECROSIS FACTOR ANTIBODY;

AGE DISTRIBUTION; AUTOIMMUNE DISEASE; BLINDNESS; BRAIN BIOPSY; BRAIN DISEASE; BRAIN INFARCTION; BRANCH RETINAL ARTERY OCCLUSION; CLINICAL FEATURE; COCHLEA; COCHLEA PROSTHESIS; CORPUS CALLOSUM; CORTICOSTEROID THERAPY; DEMENTIA; DERMATOMYOSITIS; DIAGNOSTIC ERROR; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DISEASE COURSE; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG PULSE THERAPY; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EARLY DIAGNOSIS; ENCEPHALOMYELITIS; EYE FUNDUS; FLUORESCENCE ANGIOGRAPHY; GRAY MATTER; HEADACHE; HEARING IMPAIRMENT; HEARING LOSS; HUMAN; IMMUNOPATHOGENESIS; IMMUNOSUPPRESSIVE TREATMENT; LEPTOMENINX; LONG TERM CARE; LOW DRUG DOSE; MICROVASCULATURE; MORNING DOSAGE; MULTIPLE CYCLE TREATMENT; MULTIPLE SCLEROSIS; NEUROLOGIC DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; PARANOIA; PLASMAPHERESIS; RECURRENT DISEASE; REVIEW; SEX DIFFERENCE; SUSAC SYNDROME; TREATMENT RESPONSE; VERTIGO; WHITE MATTER;

EID: 38749099406     PISSN: 10928480     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11940-008-0008-y     Document Type: Review

References (53)

1. Susac JO, Hardimann JM, Selhorst JB: Microangiopathy of the brain and retina. Neurology 1979, 29:313-316.
2. Susac JO: Susac's syndrome: the triad of microangiopathy of the brain and retina with hearing loss in women. Neurology 1994, 44:591-593.
3. Susac JO, Murtagh FR, Egan RA, et al.: MRI findings in Susac's syndrome. Neurology 2003, 61:1783-1787.
4. Susac JO: Susac's syndrome. AJNR Am J Neuroradiol 2004, 25:351-352.
5. Saenz R, Quan AW, Magalhaes A, Kish K: MRI of Susac's syndrome. AJR Am J Roentgenol 2005, 184:1688-1690.
6. Gross M, Eliashar R: Update on Susac's syndrome. Curr Opin Neurol 2005, 18:311-314.
7. Egan RA, Ha Nguyen T, Gass DM, et al.: Retinal arterial wall plaques in Susac syndrome. Am J Ophthalmol 2003, 135:483-486.
8. O'Halloran HS, Pearson PA, Lee WB, et al.: Microangiopathy of the brain, retina, and cochlea (Susac syndrome): a report of five cases and a review of the literature. Ophthalmoscopy 1998, 105:1038-1044.
9. Fialho D, Holmes P, Riordan-Eva P, et al.: A blinding headache falling on deaf ears (Susac's syndrome). Pract Neurol 2002, 2:358-361.
10. Petty GW, Engel AG, Younge B, et al.: Retinocochleocerebral vasculopathy. Medicine (Baltimore) 1998, 77:12-40.
11. Petty GW, Matteson EL, Younge BR: Recurrence of Susac syndrome. Mayo Clin Proc 2001, 76:958-960.
12. Gass DJW, Tiedman J, Thomas MA: Idiopathic recurrent branch retinal artery occlusion. Ophthalmology 1986, 93:1148-1157.
13. Fox RJ, Costello F, Judkins AR, et al.: Treatment of Susac syndrome with gamma globulin and corticosteroids. J Neurol Sci 2006, 251:17-20.
14. Heiskala H, Somer H, Kovanen J, et al.: Microangiopathy with encephalopathy, hearing loss and retinal arteriolar occlusions: two new cases. J Neurol Sci 1988, 86:239-250.
15. Kaminska EA, Sadler M, Sangalang V, et al.: Microangiopathic syndrome of encephalopathy, retinal vessel occlusion, and hearing loss [abstract]. Can J Neurol Sci 1990, 17:241.
16. Monteiro MLR, Swanson RA, Coppeto JR, et al.: A microangiopathic syndrome of encephalopathy, hearing loss, and retinal arteriolar occlusions. Neurology 1985, 35:1113-1121.
17. Bogousslavsky J, Gaio J-M, Caplan LR, et al.: Encephalopathy, deafness and blindness in young women: a distinct retinocochleocerebral arteriolopathy? J Neurol Neurosurg Psychiatry 1989, 52:43-46.
18. Do TH, Fisch C, Evoy F: Susac syndrome: report of four cases and review of the literature. AJNR Am J Neuroradiol 2004, 25:382-388.
19. Magro CM: Susac's syndrome: an autoimmune endotheliopathy. Paper presented at the 1st Susac's Syndrome Symposium, held at Ohio State University, Columbus, OH, April 2005.
20. Crowson AN, Magro CM: The role of microvascular injury in the pathogenesis of cutaneous lesions of dermatomyositis. J Hum Pathol 1996, 31:515-519.
21. Crowe WE, Bove KE, Levinson JE, et al.: Clinical and pathogenetic implications of histopathology in childhood polydermatomyositis. Arthritis Rheum 1982, 25:126-129.
22. Kissel JT, Mendell JR, Rammohan KW: Microvascular deposition of complement membrane attack complex in dermatomyositis. N Engl J Med 1986, 314:329-334.
23. Dalakas MC: Immunopathogenesis of inflammatory myopathies. Ann Neurol 1995, 37:S74-S86.
24. Greenberg SA, Amato AA: Uncertainties in the pathogenesis of adult dermatomyositis. Curr Opin Neurol 2004, 17:359-364.
25. Gordon DL, Hayreh SS, Adams HP Jr: Microangiopathy of the brain, retina, and ear: improvement without immunosuppressive therapy. Stroke 1991, 22:933-937.
26. Turner BW, Digre KB, Shelton C: Susac syndrome. Otolaryngol Head Neck Surg 1998, 118:866-867.
27. Aubarr-Cohen F, Klein I, Alexandra JF, et al.: Long-term outcome in Susac syndrome. Medicine (Baltimore) 2007, 86:93-102.
28. Tashima K, Uyama E, Hashimoto Y, et al.: Susac's syndrome: beneficial effects of corticosteroid therapy in a Japanese case. Intern Med (Tokyo) 2001, 40:135-139.
29. Coppeto JR, Currie JN, Monteiro MLR, et al.: Syndrome of arterial-occlusive retinopathy and encephalopathy. Am J Ophthalmol 1984, 98:189-202.
30. MacFadyen DJ, Schneider RJ, Chisholm IA: A syndrome of brain, inner ear, and retinal microangiopathy. Can J Neurol Sci 1987, 14:315-318.
31. Papo T, Biousse V, Lehoang P, et al.: Susac syndrome. Medicine (Baltimore) 1998, 77:3-11.
32. Hahn JS, Lannin WC, Sarwal MM: Microangiopathy of brain, retina, and inner ear (Susac's syndrome) in an adolescent female presenting as acute disseminated encephalomyelitis. Pediatrics 2004, 114:276-281.
33. Papeix C, Laloum L, Richet A, et al.: Susac's syndrome: improvement with combined cyclophosphamide and intravenous immunoglobulin therapy. Rev Neurol (Paris) 2000, 156:783-785.
34. Erer S, Boz M, Taskapilioglu, et al.: The first Susac's syndrome case in Turkey. J Neurol Sci 2006, 251:134-137.
35. Gruhn N, Pedersen LK, Nielsen NV: Susac's syndrome: the first case report in a Nordic country, with an 8-year follow-up. Acta Ophthalmol Scand 2005, 83:757-758.
36. Rennebohm RM, Susac JO: Treatment of Susac's syndrome. J Neurol Sci 2007, 257:215-220.
37. Susac JO, Egan RA, Rennebohm R, Lubow M: Susac's syndrome: 1975-2005 microangiopathy/autoimmune endotheliopathy. J Neurol Sci 2007, 257:270-272.
38. Rennebohm R: Juvenile dermatomyositis. Pediatr Ann 2002, 31:426-433.
39. Klein-Gitelman MS, Warers T, Pachman LM: The economic impact of intermittent high-dose intravenous versus oral corticosteroid treatment of juvenile dermatomyositis. Arthritis Care Res 2000, 13:360-368.
40. Dalakas MC: High-dose intravenous immunoglobulin in inflammatory myopathies: experience based on controlled clinical trials. Neurol Sci 2003, 24:S256-S259.
41. Dalakas MC: The use of intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: evidence-based indications and safety profile. Pharmacol Ther 2004, 102:177-193.
42. Ramanan AV, Campbell-Webster N, Ota S, et al.: The effectiveness of treating juvenile dermatomyositis with methotrexate and aggressively tapered corticosteroid. Arthritis Rheum 2005, 52:3570-3578.
43. Kameda H, Nagasawa H, Ogawa H, et al.: Combination therapy with corticosteroids, cyclosporin A, and intravenous pulse cyclophosphamide for acute/subacute interstitial pneumonia in patients with dermatomyositis. J Rheumatol 2005, 32:1719-1726.
44. Riley P, Maillard SM, Wedderburn LR, et al.: Intravenous cyclophosphamide pulse therapy in juvenile dermatomyositis. A review of efficacy and safety. Rheumatology (Oxford) 2004, 43:491-496.
45. Nakashima S, Mori M, Miyamae T, et al.: Intravenous cyclophosphamide pulse therapy for refractory juvenile dermatomyositis [in Japanese]. Ryumachi 2002, 42:895-902.
46. Edge JC, Outland JD, Dempsey JR, et al.: Mycophenylate mofetil as an effective corticosteroid sparing therapy for recalcitrant dermatomyositis. Arch Dermatol 2006, 142:65-69.
47. Majithia V, Harisdangkul V: Mycophenylate mofetil (Cellcept): an alternative therapy for autoimmune inflammatory myopathy. Rheumatology (Oxford) 2005, 44:386-389.
48. Nadiminni U, Arbiser JL: Rapamycin (sirolimus) as a steroid sparing agent in dermatomyositis. J Am Acad Dermatol 2005, 52(Suppl 1):17-19.
49. Hengstman GL, van den Hoogen FH, Barrera P, et al.: Successful treatment of dermatomyositis and polymyositis with anti-tumor-necrosis-factor-alpha: preliminary observations. Eur Neurol 2003, 50:10-15.
50. Levine TD: Rituximab in the treatment of dermatomyositis: an open-label pilot study. Arthritis Rheum 2005, 52:601-607.
51. Chiappetta N, Steier J, Gruber B: Rituximab in the treatment of refractory dermatomyositis. J Clin Rheumatol 2005, 11:264-266.
52. Fisler RE, Liang MG, Fuhlbrigge RC, et al.: Aggressive management of juvenile dermatomyositis results in improved outcome and decreased incidence of calcinosis. J Am Acad Dermatol 2002, 47:505-511.
53. Austin HA III, Klippel JH, Balow JE, et al.: Therapy of lupus nephritis: controlled trial of prednisone and cytotoxic drugs. N Engl J Med 1986, 314:614-619.